- Home
- TLX vs GH Comparison
TLX vs GH Comparison
Compare TLX & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLX
- GH
- Stock Information
- Founded
- TLX 2015
- GH 2011
- Country
- TLX Australia
- GH United States
- Employees
- TLX N/A
- GH N/A
- Industry
- TLX Biotechnology: Pharmaceutical Preparations
- GH Medical Specialities
- Sector
- TLX Health Care
- GH Health Care
- Exchange
- TLX Nasdaq
- GH Nasdaq
- Market Cap
- TLX 5.7B
- GH 4.9B
- IPO Year
- TLX N/A
- GH 2018
- Fundamental
- Price
- TLX $17.15
- GH $49.14
- Analyst Decision
- TLX Strong Buy
- GH Strong Buy
- Analyst Count
- TLX 2
- GH 20
- Target Price
- TLX $22.00
- GH $54.35
- AVG Volume (30 Days)
- TLX 24.4K
- GH 2.2M
- Earning Date
- TLX 01-01-0001
- GH 08-06-2025
- Dividend Yield
- TLX N/A
- GH N/A
- EPS Growth
- TLX 798.14
- GH N/A
- EPS
- TLX 0.09
- GH N/A
- Revenue
- TLX $484,687,790.00
- GH $773,996,000.00
- Revenue This Year
- TLX N/A
- GH $23.14
- Revenue Next Year
- TLX N/A
- GH $21.42
- P/E Ratio
- TLX $189.97
- GH N/A
- Revenue Growth
- TLX 55.85
- GH 28.20
- 52 Week Low
- TLX $13.61
- GH $20.14
- 52 Week High
- TLX $30.36
- GH $52.92
- Technical
- Relative Strength Index (RSI)
- TLX N/A
- GH 62.17
- Support Level
- TLX N/A
- GH $48.00
- Resistance Level
- TLX N/A
- GH $51.71
- Average True Range (ATR)
- TLX 0.00
- GH 2.67
- MACD
- TLX 0.00
- GH 0.39
- Stochastic Oscillator
- TLX 0.00
- GH 78.60
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.